Share this
Cooley Named Licensing & Collaboration Firm of the Year by LMG Life Sciences
Two Cooley partners also named winners in their practice areas • September 9, 2022
Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche
Poseida to receive $110 million upfront, with overall potential deal value of up to $6 billion • August 5, 2022
The Legal 500 US 2022 Highlights Cooley
June 17, 2022
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Cell Therapy Programs
June 9, 2022
Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb
December 22, 2021
Poseida Therapeutics Enters Research Collaboration With Takeda to Develop Novel Gene Therapies
November 17, 2021
Legal 500 US 2021 Highlights Cooley
July 19, 2021
Scrip Asks…What Does 2021 Hold for Biopharma? Part 5: Business Environment and Strategy
Scrip • February 22, 2021
Merus Enters Collaboration With Eli Lilly to Develop New Generation of Cancer Treatments
February 3, 2021
Cooley Advises on Follow-On Offerings for Reata + argenx
Transactions total more than $1 billion • December 5, 2019
Therachon Agrees to Sell to Pfizer for Up to $810 Million
May 21, 2019
Agilis Biotherapeutics Sells to PTC for $200 Million
Combination expands gene therapy programs for treatment of rare diseases • July 30, 2018
Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech
June 26, 2018
Vir Acquires Humabs BioMed and Enters Six Strategic Partnerships
Transactions with biotech firms + research universities lay out pipeline to address infectious diseases • January 10, 2018
Sucampo Acquires Vtesse
April 12, 2017
Prasco Acquires Rights to Authorized Generic of Adderall XR®
October 17, 2016
Selecta Biosciences – $74 Million IPO
July 25, 2016
Merus IPO – $61 Million
June 1, 2016
Cardioxyl Sells to Bristol-Myers Squibb for up to $2 Billion
November 5, 2015
Celyad Completes $100 Million IPO
July 27, 2015
NewLink Will License Ebola Vaccine to Merck
December 9, 2014
Vitae Pharmaceuticals Completes Initial Public Offering
October 10, 2014
Cooley Advises FORMA on $600 Million Collaboration with Celgene
April 11, 2014
Cooley Advises Eagle on Initial Public Offering
February 26, 2014
Cooley Advises Underwriters on Egalet Corporation IPO
February 21, 2014
Cooley Advises Underwriters on Genocea Biosciences IPO
Cooley Advises on First US IPO of 2014 for GlycoMimetics
January 23, 2014
Cooley Advises on Two Independent Billion-Dollar Life Sciences Collaborations
December 16, 2013
Cooley Advises Apollo Endosurgery in Agreement to Acquire Obesity Intervention Division of Allergan
October 29, 2013
Cooley Advises Underwriters on Onconova Therapeutics IPO
August 8, 2013
Cooley Advises Underwriters on Epizyme, Inc. Initial Public Offering
June 14, 2013
Cooley Advises FORMA Therapeutics in $200M Strategic Collaboration Deal with Celgene
April 29, 2013
Cooley Helps Cylex Use Chapter 11 Bankruptcy to Achieve Exceptional Sale Price
March 4, 2013
Cooley Recognized as Elite Top-25 Law Firm (Financial Times)
December 4, 2012
Cooley Recognized as Elite Top-25 Law Firm by Financial Times
Cooley Represents Molecular Partners in Broad Collaboration with Allergan
September 10, 2012
Cooley Advises Micromet on $1.16 Billion Sale to Amgen
January 26, 2012
Healthcare Reform Law Will Provide Cash Grants and Tax Credits for Qualifying Life Sciences Companies
Cooley Alert • March 31, 2010